The company exhibits no operating leverage, with quarterly operating losses consistently reaching $1.2 million while maintaining zero revenue generation.
| Sales/Revenue | 0 | 17K | 0 | 0 | 86K | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | -100% | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 844K | 16K | 15K | 15K | 7K | 0 | 1K | 0 | 0 |
| COGS % of Revenue | - | 4964.71% | - | - | 17.44% | - | - | - | - | - |
| Gross Profit | 0 | -827K | -16K | -15K | 71K | -7K | 0 | -1K | 0 | 0 |
| Gross Margin % | - | -4864.71% | - | - | 82.56% | - | - | - | - | - |
| Gross Profit Growth % | - | -5068.75% | -6.67% | -121.13% | 1114.29% | - | 100% | - | - | - |
| Operating Expenses | 4.13M | 4.16M | 14.66M | 9.58M | 8.87M | 7.21M | 1.67M | 689K | 500K | 877K |
| OpEx % of Revenue | - | 24470.59% | - | - | 10312.79% | - | - | - | - | - |
| Selling, General & Admin | 3.38M | 3.02M | 2.95M | 3.55M | 4.45M | 4.35M | 1.32M | 553K | 277K | 376K |
| SG&A % of Revenue | - | 17788.24% | - | - | 5170.93% | - | - | - | - | - |
| Research & Development | 576K | 1.14M | 11.71M | 6.04M | 4.42M | 2.86M | 354K | 136K | 223K | 504K |
| R&D % of Revenue | - | 6682.35% | - | - | 5141.86% | - | - | - | - | - |
| Other Operating Expenses | 173K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -4.13M | -4.99M | -14.67M | -9.58M | -8.87M | -7.21M | -1.67M | -689K | -500K | -880K |
| Operating Margin % | - | -29335.29% | - | - | -10312.79% | - | - | - | - | - |
| Operating Income Growth % | - | 66.01% | -53.1% | -8.06% | -23.04% | -331.36% | -142.53% | -37.8% | 43.18% | - |
| EBITDA | -3.94M | -4.21M | -14.66M | -9.57M | -8.85M | -7.2M | -1.67M | -688K | 0 | 0 |
| EBITDA Margin % | - | -24782.35% | - | - | -10295.35% | - | - | - | - | - |
| EBITDA Growth % | 77.87% | 71.26% | -53.17% | -8.08% | -22.96% | -331.2% | -142.73% | - | - | - |
| D&A (Non-Cash Add-back) | 190K | 774K | 16K | 15K | 15K | 7K | 1K | 1K | 500K | 880K |
| EBIT | -4.13M | -4.99M | -14.57M | -9.58M | -8.77M | -7.23M | -1.67M | -689K | -503K | -880K |
| Net Interest Income | 3K | 110K | 87K | 22K | 99K | -10K | -985.95K | -540.41K | 0 | 0 |
| Interest Income | 3K | 120K | 101K | 406K | 160K | 0 | 1.05K | 588 | 0 | 245K |
| Interest Expense | 0 | 10K | 14K | 384K | 61K | 10K | 987K | 541K | 324K | 0 |
| Other Income/Expense | 53K | -27K | 93K | 248K | 86K | -32K | -2.16M | -590K | -328K | -242K |
| Pretax Income | -4.08M | -5.01M | -14.58M | -9.34M | -8.78M | -7.24M | -3.83M | -1.28M | -828K | -1.12M |
| Pretax Margin % | - | -29494.12% | - | - | -10212.79% | - | - | - | - | - |
| Income Tax | 8K | 8K | 8K | 8K | 9K | 6K | 220K | 0 | 4K | 0 |
| Effective Tax Rate % | -0.2% | -0.16% | -0.05% | -0.09% | -0.1% | -0.08% | -5.74% | 0% | -0.48% | 0% |
| Net Income | -4.09M | -4.84M | -14.59M | -9.34M | -8.79M | -7.25M | -4.05M | -1.82M | -828K | -2.09M |
| Net Margin % | - | -28458.82% | - | - | -10223.26% | - | - | - | - | - |
| Net Income Growth % | 76.88% | 66.84% | -56.12% | -6.28% | -21.34% | -78.78% | -122.69% | -119.81% | 60.38% | - |
| Net Income (Continuing) | -4.09M | -5.02M | -14.59M | -9.34M | -8.79M | -7.25M | -4.05M | -1.28M | -828K | -1.12M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 747K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -48.10 | -7.47 | -804.00 | -4283.23 | -4948.02 | -4430.82 | -2076.30 | -1552.86 | -1208.00 | -906.25 |
| EPS Growth % | 98.84% | 99.07% | 81.23% | 13.44% | -11.67% | -113.4% | -33.71% | -28.55% | -33.3% | - |
| EPS (Basic) | - | -7.47 | -804.00 | -4283.23 | -4948.02 | -4430.82 | -2076.30 | -1552.86 | -363.25 | -916.75 |
| Diluted Shares Outstanding | 84.94K | 647.97K | 18.14K | 2.18K | 1.78K | 1.64K | 1.95K | 1.55K | 2.31K | 2.31K |
| Basic Shares Outstanding | 84.92K | 647.97K | 18.14K | 2.18K | 1.78K | 1.64K | 1.95K | 1.55K | 2.28K | 2.28K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Imminent liquidity and dilution risk
As reported in recent financial filings, PRFX maintains a cost structure dominated by R&D and SG&A, with quarterly operating expenses consistently exceeding $1 million, reflecting the capital-intensive nature of its ongoing Phase 3 clinical trials for the PRF-110 delivery platform.
The company's cost structure is entirely decoupled from revenue generation, as it remains in a pre-commercial phase. The persistent SG&A and R&D spend suggests that management is prioritizing clinical milestones over immediate cost containment, which warrants close monitoring given the limited cash reserves.
Based on the provided income statement data, PRFX exhibits no operating leverage, as the company has failed to generate meaningful revenue while sustaining quarterly operating losses that reached $1.2 million in the most recent period, indicating a lack of scalable operational efficiency.
The absence of revenue means that every dollar spent on clinical development and administrative overhead directly expands the net loss. Investors should interpret this as a binary risk profile where operational efficiency is secondary to the successful completion of clinical trials.
According to the company's historical income statements, the quality of earnings is currently non-existent, as net income remains consistently negative and EPS dilution is exacerbated by the ongoing reliance on equity-based financing to fund operations.
The presence of stock-based compensation, while relatively modest, adds a layer of dilution that further penalizes existing shareholders during this pre-revenue phase. The lack of non-operating income or tax benefits suggests that the reported net losses are a pure reflection of the company's cash burn.
As indicated by the financial snapshot, the company's cash-to-burn ratio appears increasingly unsustainable, with quarterly losses of $1.2 million rapidly depleting the reported $4.166 million cash balance, which suggests a high probability of near-term dilutive capital raises to maintain operations.
Short-term observers may focus on the potential for clinical success, but the income statement reveals a structural vulnerability regarding liquidity. The inability to self-fund through operations means that the company is entirely dependent on external capital markets, which may be unfavorable given the current economic environment.
Quick answers to the most common questions about buying PRFX stock.
For fiscal year 2025, PRF Technologies Ltd. (PRFX) reported total revenue of $0.0M.
PRF Technologies Ltd. (PRFX) reported a net loss of $4.8M for the fiscal year ending 2025.
PRF Technologies Ltd. (PRFX) reported an operating income of $-5.0M, resulting in an operating profit margin of -29335.3%. This margin reflects the operational efficiency of the business before interest and taxes.
PRF Technologies Ltd. (PRFX) generated $-0.8M in gross profit for the year, representing a gross profit margin of -4864.7%. This demonstrates the company's core pricing power and production efficiency.